What blood-based tumor marker can be used for colorectal (colon and rectal) cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Blood-Based Tumor Marker for Colorectal Cancer

Carcinoembryonic antigen (CEA) is the established blood-based tumor marker for colorectal cancer, though it should NOT be used for screening. 1

Clinical Applications of CEA

What CEA Should Be Used For:

Postoperative Surveillance (Most Important Use)

  • Measure CEA every 3 months in patients with stage II or III disease for at least 3 years after diagnosis 1
  • Only perform this surveillance if the patient is a candidate for surgery or systemic therapy
  • Wait until chemotherapy is finished before starting surveillance, as chemotherapy can falsely elevate CEA levels 1
  • An elevated CEA (≥5 ng/mL), if confirmed by retesting, warrants further evaluation for metastatic disease
  • CEA is the most cost-effective test for detecting potentially resectable metastases, particularly liver metastases 2, 3

Monitoring Metastatic Disease

  • CEA is the marker of choice for monitoring metastatic colorectal cancer during systemic therapy 1
  • Measure at the start of treatment and every 1-3 months during active treatment
  • Persistently rising values above baseline suggest progressive disease even without radiographic confirmation
  • Caution: Spurious early rises may occur during the first 4-6 weeks of new therapy, especially with oxaliplatin 1

Preoperative Staging

  • May be ordered preoperatively if it would assist in staging and surgical treatment planning 1
  • Elevated preoperative CEA (≥5 ng/mL) correlates with poorer prognosis, but insufficient data support using it to determine adjuvant therapy 1

What CEA Should NOT Be Used For:

  • NOT recommended for screening in asymptomatic populations 2, 1, 2
  • An elevated CEA alone does NOT justify starting systemic therapy for presumed metastatic disease 1

Other Blood Markers: Not Recommended

The ASCO guidelines explicitly state insufficient evidence for these markers 1:

  • CA 19-9: Not recommended for screening, diagnosis, staging, surveillance, or monitoring
  • p53: Insufficient data
  • ras oncogene: Insufficient data
  • DNA ploidy/flow cytometry: Should not be used

Emerging Blood-Based Tests

New Cell-Free DNA Tests (2024-2025)

The FDA-approved Shield test (Guardant) and other emerging blood tests show 4, 5:

  • Sensitivity for CRC: 83.1% (Shield)
  • Specificity: 89.6%
  • Critical limitation: Only 13% sensitivity for advanced precancerous lesions
  • Lower sensitivity for stage I CRC (55-57%) compared to stool-based tests

Current Recommendation: Blood-based cell-free DNA tests should only be offered to patients who decline or do not complete preferred screening tests (stool-based tests or colonoscopy) 5. They are inferior to established screening methods for cancer prevention due to poor detection of precancerous lesions.

Clinical Pitfalls to Avoid

  1. Don't use CEA for screening - it lacks sensitivity and specificity for early cancer detection 2, 1
  2. Don't start treatment based on CEA alone - always confirm with imaging or biopsy 1
  3. Don't misinterpret early CEA rises during chemotherapy - wait 4-6 weeks, especially with oxaliplatin 1
  4. Don't order CEA surveillance in patients who aren't surgical candidates - it won't change management 1
  5. Don't confuse newer blood tests with established markers - cell-free DNA tests are for screening (with limitations), while CEA is for surveillance and monitoring established disease

Bottom Line

For established colorectal cancer, CEA remains the only clinically validated blood-based tumor marker with proven utility for postoperative surveillance and monitoring metastatic disease 1. It provides approximately 80% sensitivity for detecting recurrence with a 5-month lead time, making it particularly valuable for identifying resectable liver metastases 2, 3. However, CEA has no role in screening asymptomatic individuals.

References

Related Questions

In a 28-year-old patient with a family history of lung cancer, colorectal cancer, and an unspecified malignancy, are there indications for accelerated cancer screening?
At what age should a 40-year-old woman with a history of breast cancer begin colorectal cancer screening?
What imaging studies and laboratory tests should be ordered for surveillance in a 47‑year‑old woman who underwent curative resection and completed adjuvant chemotherapy for colon cancer?
In a 63-year-old man with multiple lung nodules and a 4 cm left‑lung mass, which of the following primary cancers most rarely metastasizes to the lung: breast, kidney, melanoma, colon, or cervical cancer?
Which finding on further workup is most likely in a 53-year-old woman who suddenly collapsed, is hypotensive, tachycardic, hypoxemic, has elevated jugular venous pressure, clear lung fields, and a recent diagnosis of colon cancer?
What are the appropriate oral and topical treatment options for a groin abscess?
What is the appropriate evaluation and management for a patient presenting with negative myoclonus?
In a 37-year-old woman with painful, rapidly enlarging, rubbery lumbar subcutaneous nodules that feel fatty on ultrasound, recent idiopathic urticaria, chronic lymphadenopathy, fatigue, and pain that improves with prednisone, what diagnoses should be considered?
In a patient with deep lumbar nodules that are not visible on the skin surface and intermittent numbness of the right buttock, does this additional information alter the clinical assessment?
How many albuterol solution vials (2.5 mg in 3 mL) should be ordered for nebulizer treatment?
Is there evidence supporting the use of topical povidone‑iodine and tea‑tree oil for treatment of molluscum contagiosum?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.